300529.SZ SHZ
Jafron Biomedical Co.,Ltd.
1W: +0.0%
1M: -3.2%
3M: -5.8%
YTD: -24.9%
1Y: -34.5%
3Y: -29.1%
5Y: -79.9%
¥15.27 ($2.28)
+0.34 (+2.28%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Cash Flow Trends
Operating Cash Flow
$1.1B
+14.6% ▲
5Y CAGR: +12.5%
Capital Expenditures
$235M
+4.9% ▲
5Y CAGR: +1.3%
Free Cash Flow
$816M
+21.9% ▲
5Y CAGR: +17.6%
Dividends Paid
$340M
+39.5% ▲
Buybacks
$371M
+3.0% ▲
Net Change in Cash
-$1.1B
-595.3% ▼
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | $873M | $1.2B | $881M | $426M | $820M |
| Depreciation & Amort. | $37M | $54M | $74M | $95M | $127M |
| Stock-Based Comp. | $22M | $8M | -$9M | $0 | $0 |
| Change in Working Capital | $36M | -$302K | -$102M | $292M | $28M |
| Other Non-Cash Items | -$8M | $10M | $42M | $104M | $75M |
| Operating Cash Flow | $957M | $1.2B | $884M | $917M | $1.1B |
| — Investing Activities — | |||||
| Capital Expenditures | -$357M | -$537M | -$476M | -$247M | -$235M |
| Acquisitions (Net) | $358M | $987K | $7M | $13M | $5M |
| Investment Purchases | -$1.3B | -$4.6B | -$2.0B | -$15M | -$4.7B |
| Investment Sales | $1.3B | $4.4B | $2.2B | $0 | $3.8B |
| Other Investing | -$357M | $0 | -$184K | $0 | $0 |
| Investing Cash Flow | -$341M | -$670M | -$306M | -$250M | -$1.1B |
| — Financing Activities — | |||||
| Net Debt Issuance | $0 | $998M | $296M | $418M | -$326M |
| Stock Repurchased | -$8M | -$500M | -$5M | -$383M | -$371M |
| Dividends Paid | -$378M | -$531M | -$717M | -$562M | -$340M |
| Other Financing | $72M | $198M | $72M | -$309M | $48M |
| Financing Cash Flow | -$313M | $165M | -$366M | -$452M | -$990M |
| Net Change in Cash | $303M | $744M | $212M | $215M | -$1.1B |
| Cash End of Period | $1.6B | $2.3B | $2.5B | $2.7B | $1.7B |
| Free Cash Flow | $600M | $712M | $408M | $669M | $816M |